CAH Stock Recent News

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Aaron Alt, CFO at Cardinal Health (CAH), joins Diane King Hall at the NYSE set to discuss the company's financial outlook. He describes the drugmaker's share buyback plans and recent FY25 guidance raise.

Drug distributor Cardinal Health raised its annual adjusted profit forecast on Thursday, banking on demand for costly specialty medicines and branded drugs at its pharmaceuticals unit.

Key announcements: Raising FY25 non-GAAP diluted EPS guidance to $8.15 to $8.20 1 Establishing preliminary FY26 non-GAAP diluted EPS guidance of $9.10 to $9.30 (13% growth at the mid-points)2 Confirming long-term target of 12% to 14% non-GAAP diluted EPS CAGR for FY26 to FY283 Raising long-term target for Pharmaceutical and Specialty Solutions profit to 5% to 7% normalized growth3,4 Raising long-term target for Other profit to ~10% normalized growth3,4,5 Updating GMPD long-term target to $50M+ of profit growth per year after FY26 Expecting at least $10B in total adjusted free cash flow over next three years Raising baseline share repurchase plans to at least $750M per year Company reiterating strategic priorities and providing updates across its businesses DUBLIN, Ohio , June 12, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today will host an Investor Day beginning at 9:00 a.m. ET, where management will detail its growth strategies to maximize the company's potential for all stakeh

BofA Securities analyst Allen Lutz reiterated the Buy rating on Cardinal Health, Inc. CAH, raising the price forecast from $165 to $170.

Jim Cramer breaks down why he's keeping an eye on shares of Cardinal Health.

Kendall DL™ Multi System simplifies patient monitoring, drives efficiencies for providers  DUBLIN, Ohio , June 4, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today the U.S. launch of its multi-parameter, single-patient use monitoring cable and lead wire system that enables the continuous monitoring of cardiac activity, blood oxygen level and temperature with one point of connection. The new Kendall DL™ Multi System is designed to travel with the patient from admission to discharge for smooth transport.